Skip to main content

Advertisement

Table 2 % inhibition in ALT and AST levels with respect to CCl 4 group, % increase in ALT and AST levels with respect to VC group and alleviation of the hepatic damage in terms of fold reduction in increased enzyme levels change with respect to CCl 4

From: Sesamol loaded solid lipid nanoparticles: a promising intervention for control of carbon tetrachloride induced hepatotoxicity

  ALT Levels AST Levels
Groups Dose (mg/kg) % Inhibition versus CCl4group (% increase with respect to VC) Alleviation (Fold change with respect to CCl4) % Inhibition versus CCl4group (% increase with respect to VC) Alleviation (Fold change with respect to CCl4)
S-SLNsa 8 52.59 ± 2.37 (1073.93 ± 166.43) 2.12 75.68 ± 3.61 (139.52 ± 51.44) 4.13
FS 8 34.12 ± 3.69 (1677.97 ± 298.08) 1.51 51.84 ± 5.88 (356.79 ± 53.86) 2.09
SILYa 25 48.84 ± 3.15 (1173.98 ± 166.43) 1.95 75.97 ± 4.04 (129.95 ± 31.47) 4.18
SR - 19.09 ± 1.38 (1677.97 ± 298.08) 1.23 5.22 ± 2.22 (837.98 ± 148.87) 1.05
  1. Data are expressed as mean ± S.D (n = 6) except for fold change. aAll the groups are significantly different from each other at p ≤ 0.001 except for those marked similarly. CCl4 increased the ALT and AST levels by 2570.07% and 890.89% respectively with respect to VC. Actual values for CCl4 and VC for ALT are 7.21 ± 0.35 and 0.27 ± 0.05 respectively; AST are 6.50 ± 0.61 and 0.93 ± 0.20 respectively. The actual values are expressed in units of nmoles/nL.